Figure 4.
PFS was longer in patients who received primary kidney tumor resection. Local therapy for the metastatic site seemed to benefit patients in the IMDC favorable-risk group (A) but not those in the IMDC intermediate-risk group (B). IMDC, International Metastatic RCC Database Consortium; PFS, progression-free survival.